3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
1
Gastrointestinal
1
Conditions
Breast Neoplasms
60
Prostatic Neoplasms
52
Squamous Cell Carcinoma of Head and Neck
43
Carcinoma, Non-Small-Cell Lung
39
Head and Neck Neoplasms
37
Lung Neoplasms
35
Lymphoma
34
Leukemia
22
Brain Neoplasms
20
Central Nervous System Neoplasms
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Glioblastoma
18
Uterine Cervical Neoplasms
17
Sarcoma
17
Rectal Neoplasms
17
Lymphoma, Follicular
16
Esophageal Squamous Cell Carcinoma
16
Esophageal Neoplasms
15
Lymphoma, Large B-Cell, Diffuse
14
Hodgkin Disease
14
Burkitt Lymphoma
14
Adenocarcinoma of Lung
13
Oligodendroglioma
12
Lymphoma, Non-Hodgkin
12
Neoplasm Metastasis
11
Astrocytoma
11
Rhabdomyosarcoma
10
Lymphoma, Large-Cell, Immunoblastic
10
Neuroblastoma
9
Nasopharyngeal Carcinoma
9
Interventions
pembrolizumab
95
Cisplatin
35
Paclitaxel
27
Carboplatin
27
Docetaxel
17
lenvatinib
15
Fluorouracil
14
Saline Solution
13
Capecitabine
12
Pemetrexed
10
Gemcitabine
10
Oxaliplatin
9
Cetuximab
7
Albumin-Bound Paclitaxel
7
olaparib
6
epacadostat
6
Bevacizumab
6
130-nm albumin-bound paclitaxel
6
Leucovorin
5
enzalutamide
4
Etoposide
4
trifluridine tipiracil drug combination
3
regorafenib
3
belzutifan
3
Prednisone
3
Irinotecan
3
Glucose
3
Dexamethasone
3
liposomal doxorubicin
2
durvalumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Radiotherapy
×
Clear all
NCT04210115
2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
703 enrolled
NCT03040999
2026-02-04
KEYNOTE-412
Merck Sharp & Dohme LLC
Phase 3
Completed
804 enrolled
20 charts